-
Criminal Charges Against Former Valeant Exec 'Not Pertinent But Underscores Cautious Outlook'
Friday, November 18, 2016 - 1:45pm | 282Read More...Federal prosecutors in the state of New York charged former Valeant Pharmaceuticals Intl Inc (NYSE: VRX) executive Gary Tanner for alleged colluding with Andrew Davenport, who was Philidor Rx's CEO. It was further alleged that $40 million was routed toward Davenport through various entities, and...
-
An Update On The Ackman Trades
Wednesday, November 9, 2016 - 2:19pm | 505Read More...Pershing Square Holding, the hedge fund controlled by billionaire Bill Ackman, once more brought home a bad report card. Monthly portfolio update issued by the company for October showed that net performance of the fund was down 22.5 percent in the year-to-date period. This is despite the broader...
-
Valeant Responds To Former CEO's Stock Transactions: Not A Reflection Of Our Ongoing Viability
Thursday, July 14, 2016 - 10:55am | 336Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) reacted Thursday to the recent stock transactions made by its former CEO Michael Pearson. The pharmaceutical firm still believes Pearson remained a significant shareholder with more than 3.5 million shares. The ex-CEO is required to retain one...
-
5 Takeaways From Vanity Fair's New Valeant Expose
Monday, June 6, 2016 - 12:18pm | 524Read More...A new Vanity Fair article by Bethany McLean attempts to unwind the complex and convoluted story of Valeant Pharmaceuticals Intl Inc (NYSE: VRX). Although the Valeant story is far from over, here are five things you need to know about Vanity Fair’s take on the situation. 1. Valeant’s...
-
User Questions When Bill Ackman Had Access To Valeant Earnings
Tuesday, May 10, 2016 - 10:36am | 380Read More...A series of emails sent by Bill Ackman, including two to former Valeant Pharmaceuticals Intl Inc (NYSE: VRX) CEO Michael Pearson, were posted on Twitter by @piermont_morgan on Tuesday morning. The user seems to imply Ackman was asking for and discussing non-public earnings and guidance...
-
Valeant Spikes 6%, WSJ Says Company Close To Hiring Perrigo's Chief As New CEO
Friday, April 22, 2016 - 8:06am | 265Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) spiked higher by more than 6 percent early Friday morning following reports the company is close to naming a new CEO. According to The Wall Street Journal, Valeant is finalizing a contract with Perrigo Company plc (NYSE: PRGO)'s Chief Executive...
-
Valeant Credit Analysts Disagreed About Its Debt Earlier This Month
Thursday, March 31, 2016 - 2:14pm | 337Read More...A pair of top Wall Street firms aren’t on the same page when it comes to the outlook for Valeant Pharmaceuticals Intl Inc (NYSE: VRX) senior notes. In a March 21 report, Citi analyst Murali Ganti said that the resignation of CEO Michael Pearson and the addition of Bill Ackman to the board...
-
Cramer: Valeant Is A 'Great Mystery'
Monday, March 21, 2016 - 2:26pm | 398Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading up more than 10 percent on Monday afternoon, after the company announced that CEO J. Michael Pearson was leaving, and that billionaire activist Bill Ackman had been appointed as a board director. The company also said it would...
-
Former Valeant CFO: I Did Not Engage In Improper Conduct
Monday, March 21, 2016 - 11:20am | 400Read More...On the back of news from Valeant Pharmaceuticals Intl Inc (NYSE: VRX) regarding changes to its board of directors, former CFO Howard Schiller has defended his decision to not step down from the board. In a Monday press release, the company outlined upcoming changes, including the voluntary...
-
Valeant Announces CEO Succession Plans And Financial Update; Bill Ackman Joins Board
Monday, March 21, 2016 - 9:52am | 715Read More...Amid a sinking stock price and a flurry of downgrades, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has released some progressive news In a press release, Valeant announced a search for a new CEO, Bill Ackman as a new member of the board and other internal matters such as the 10-K filing delay...
-
Valeant's New-Old CEO: What To Know
Wednesday, March 2, 2016 - 3:33pm | 350Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s Chief Executive Michael Pearson, who just got back from a two-month sick leave, has his job cut out. The Canadian pharma company is facing several issues including delayed filing of its 10-K, a potential earnings restatement, withdrawn 2016...
-
Valeant Pharma: The Empire Strikes Back
Tuesday, February 16, 2016 - 10:18am | 370Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have appreciated 17.21 percent over the past three months, while declining 0.35 percent over the past month. Rodman & Renshaw’s Raghuram Selvaraju has initiated coverage of the company with a Buy rating and price target of $150...
-
Valeant Trends Down Following Oversight Committee Release Of Docs
Tuesday, February 2, 2016 - 1:51pm | 209Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading lower by more than 3 percent early Tuesday afternoon following the release of a memorandum from the U.S. Committee on Oversight and Government Reform. The memorandum, titled "Documents Obtained by Committee from Valeant...
-
Valeant Names Howard Schiller As Interim CEO As Mike Pearson Remains In The Hospital
Wednesday, January 6, 2016 - 11:10am | 261Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading lower by more than 9 percent early Wednesday before erasing all of the losses and trading in positive territory shortly after the opening bell. Valeant Pharmaceuticals announced that Howard B. Schiller has been named as interim...
-
Valeant Confirms CEO Will Be On Medical Leave Of Absence
Monday, December 28, 2015 - 9:27am | 228Read More...Bloomberg reported on Sunday that Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s CEO Michael Pearson remains hospitalized with a "severe" case of pneumonia. Bloomberg noted that Pearson was discharged by the Morristown Medical Center, a hospital in New Jersey, but the executive is...
